

Supplemental Table e-1. Baseline Characteristics of the Study Participants

	Placebo (N=23)	Simvastatin (N=26)	P-value
Completed, per Protocol	21 (91%)	25 (96%)	0.22
Age, years	56.1 (4.9)	55.7 (4.5)	0.75
Sex, female	18 (78%)	19 (73%)	0.75
Education, years	17.0 (2.1)	16.9 (2.6)	0.81
Race, Caucasian	21 (91%)	23 (88%)	1.00
Family history of dementia in first degree relatives	1 (4.3%)	4 (15%)	0.35
<i>APOEε4 carrier</i>	8 (35%)	7 (27%)	0.76
Serum LDL, mg/dl	127 (28)	129 (29)	0.79
Serum HDL, mg/dl	78 (20)	66 (19)	0.04
Serum Triglycerides, mg/dl	98 (43)	91 (33)	0.53
CSF Aβ ₄₂ , pg/ml	515 (113)	520 (114)	0.88
CSF total-tau, pg/ml	43 (17)	38 (16)	0.32
CSF p-tau ₁₈₁ , pg/ml	31 (15)	27 (10)	0.33

Mean (standard deviation) shown for continuous variables, number (percentage) shown for categorical variables. Test results (p-value) for difference between treatment groups based on the two-sample t-test for continuous variables and Fisher's exact test for categorical variables.

Supplemental Table e-2: Neuropsychological test score changes by treatment group

	Placebo (n = 21)		Simvastatin (n = 25)		p-value *
	Baseline	12-month change	Baseline	12-month change	
HVLT-R					
Immediate recall	29.14(3.54)	1.05(3.58)	29.08(4.46)	-0.16(3.70)	0.238
Delayed recall	10.62(1.69)	0.71(1.80)	11.08(1.32)	0.60(1.12)	0.624
CVMT					
Number of correct hits	90.48(8.70)	-4.67(5.01)	94.79(5.79)	-1.63(4.55)	0.144
Number of errors	21.52(8.69)	4.67(5.01)	17.21(5.79)	1.63(4.55)	0.144
WAIS-III-LNS	11.95(2.06)	0.43(2.31)	11.88(2.01)	0.12(2.11)	0.695
ACT					
18" delay	11.76(3.08)	0.67(3.01)	12.12(2.9)	1.04(3.45)	0.883
36" delay	10.38(3.50)	-1.48(3.01)	11.24(2.86)	-0.40(2.38)	0.322
SRT 5" Delay, response time in ms	363.29(118.14)	28.48(107.89)	299.68(57.89)	-22.80(82.47)	0.766
CRT 5" Delay, response time in ms					
Yes	473.48(56.72)	-10.62(83.66)	471.72(66.70)	-6.36(40.58)	0.994
No	491.52(87.32)	6.67(70.73)	480.24(84.01)	-4.72(65.41)	0.419

Grooved Pegboard, t-score

Dominant hand	49.38(8.20)	-0.90(7.31)	48.72(12.05)	-2.56(9.99)	0.665
Non-dominant hand	49.14(11.22)	-2.52(6.52)	48.84(11.14)	-3.68(8.45)	0.618

* p-value for test of the difference in 12-month change between treatment groups based on ANCOVA after adjusting for age, sex, education, *APOE* ϵ 4 status and premorbid intelligence using the Wechsler Test of Adult Reading.

HVLT-R: Hopkins Verbal Learning Test-Revised (verbal learning and memory); CVMT: Continuous Visual Memory Test (visual learning and memory); WAIS-III-LNS: Wechsler Adult Intelligence Scale-III Letter-Number Sequencing Subtest (attention and working memory); ACT: Auditory Consonant Trigrams (attention and working memory); SRT: Simple Reaction Time (psychomotor speed); CRT: Choice Reaction Time (psychomotor speed); and Grooved Pegboard (fine motor coordination and speed).